

ReproCyc PRRS EU lyophilisate and solvent for suspension for injection for pigs

Authorised

- Porcine reproductive and respiratory syndrome virus, type 1, strain PRRS 94881, Live

Product identification

Medicine name:

ReproCyc PRRS EU lyophilisate and solvent for suspension for injection for pigs

Active substance:

Porcine reproductive and respiratory syndrome virus, type 1, strain PRRS 94881, Live

Target species:

Pig

Route of administration:

Intramuscular use

Product details

Active substance and strength:

Porcine reproductive and respiratory syndrome virus, type 1, strain PRRS 94881, Live
10000000.00 50% tissue culture infectious dose / 1.00 Dose

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Withdrawal period by route of administration:**Intramuscular use:**

-

Pig

- Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI09AD03

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Greece

Package description:

Lyophilisate: Type I amber glass vials with bromobutyl rubber stopper and aluminium seal. Solvent: High density polyethylene (HDPE) vials with a bromo- or chlorobutyl rubber stopper and aluminium seal. Cardboard box of 25 lyophilisate vials of 200 ml (100 doses) and Cardboard box of 25 solvent vials of 200 ml (100 doses).

Lyophilisate: Type I amber glass vials with bromobutyl rubber stopper and aluminium seal. Solvent: High density polyethylene (HDPE) vials with a bromo- or chlorobutyl rubber stopper and aluminium seal. Cardboard box of 25 lyophilisate vials of 100 ml (50 doses) and Cardboard box of 25 solvent vials of 100 ml (50 doses).

Lyophilisate: Type I amber glass vials with bromobutyl rubber stopper and aluminium seal. Solvent: High density polyethylene (HDPE) vials with a bromo- or chlorobutyl rubber stopper and aluminium seal. Cardboard box of 25 lyophilisate vials of 20 ml (10 doses) and Cardboard box of 25 solvent vials of 20 ml (10 doses).

Lyophilisate: Type I amber glass vials with bromobutyl rubber stopper and aluminium seal. Solvent: High density polyethylene (HDPE) vials with a bromo- or chlorobutyl rubber stopper and aluminium seal. Cardboard box of 12 lyophilisate vials of 200 ml

(100 doses) and Cardboard box of 12 solvent vials of 200 ml (100 doses).

Lyophilisate: Type I amber glass vials with bromobutyl rubber stopper and aluminium seal. Solvent: High density polyethylene (HDPE) vials with a bromo- or chlorobutyl rubber stopper and aluminium seal. Cardboard box of 12 lyophilisate vials of 100 ml (50 doses) and Cardboard box of 12 solvent vials of 100 ml (50 doses).

Lyophilisate: Type I amber glass vials with bromobutyl rubber stopper and aluminium seal. Solvent: High density polyethylene (HDPE) vials with a bromo- or chlorobutyl rubber stopper and aluminium seal. Cardboard box of 12 lyophilisate vials of 20 ml (10 doses) and Cardboard box of 12 solvent vials of 20 ml (10 doses).

Lyophilisate: Type I amber glass vials with bromobutyl rubber stopper and aluminium seal. Solvent: High density polyethylene (HDPE) vials with a bromo- or chlorobutyl rubber stopper and aluminium seal. Cardboard box of 1 lyophilisate vial of 200 ml and 1 solvent vial of 200 ml (100 doses).

Lyophilisate: Type I amber glass vials with bromobutyl rubber stopper and aluminium seal. Solvent: High density polyethylene (HDPE) vials with a bromo- or chlorobutyl rubber stopper and aluminium seal. Cardboard box of 1 lyophilisate vial of 100 ml and 1 solvent vial of 100 ml (50 doses).

Lyophilisate: Type I amber glass vials with bromobutyl rubber stopper and aluminium seal. Solvent: High density polyethylene (HDPE) vials with a bromo- or chlorobutyl rubber stopper and aluminium seal. Cardboard box of 1 lyophilisate vial of 20 ml and 1 solvent vial of 20 ml (10 doses).

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:

1/02/2016

Manufacturing sites for batch release:

Boehringer Ingelheim Vetmedica GmbH

Responsible authority:

National Organization For Medicines

Authorisation number:

65990/25-06-2020/K-0207501

Date of authorisation status change:

10/01/2022

Reference member state:

Ireland

Procedure number:

IE/V/0444/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Estonia France Germany
Greece Hungary Italy Latvia Liechtenstein Lithuania Luxembourg
Netherlands Poland Portugal Romania Slovakia Slovenia Spain
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

Summary of Product Characteristics

English (PDF)

Published on: 30/11/2025

Updated on: 13/03/2026

Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.